The EU HTA Regulation: How It Threatens Device Launches And Where The Solutions Lie
Executive Summary
Medtech needs to closely monitor how the newly adopted EU HTA Regulation is rolled out and actively seek to influence its impact to avoid major obstacles ahead. MedTech Europe’s Oliver Bisazza explains why further shaping of this new text is so critical.
You may also be interested in...
EU’s Risk Management Standard Officially Recognized In Context Of The IVDR
Only one new standard has been added to the official list of standards recognized in the context of the EU IVD Regulation in the latest update. The good news is that it is arguably one of the most needed standards by the IVD industry after the medtech quality management standard, ISO 13485.
Device/Drug Borderline: Gray Areas Remain Despite New EU Guidance
The regulation of products on the drug/device borderline has always been complex. New EU guidance aims to provide clarification, but some difficult and nuanced decision-making is still left to the manufacturer.
EU Notified Bodies Told To Comply With Russia/Belarus Sanctions
Given the ongoing conflict in Ukraine, EU medtech notified bodies have been told to comply with sanctions intended to hurt companies based in Russia and Belarus.